TIDMONC
RNS Number : 7915Z
Oncimmune Holdings PLC
23 September 2020
23 September 2020
Oncimmune Holdings plc
("Oncimmune" or the "Company")
Oncimmune to profile samples from Genentech's rheumatology
clinical trials
New contract further demonstrates Oncimmune's expanding global
footprint for ImmunoINSIGHTS
Oncimmune Holdings plc (AIM: ONC.L), the leading global
immunodiagnostics group, today announces that it has signed a
collaboration with Genentech, a member of the Roche Group, to
characterise the autoantibody profiles of patients in clinical
trials for rheumatological diseases, including Systemic Lupus
Erythematosus (SLE).
In this new project, Oncimmune will use its proprietary
NavigAID(TM) panel to characterise autoantibody profiles from trial
participants.
Following completion of this project, Genentech has the option
to expand the contract to profile additional samples.
SLE is a chronic, incurable autoimmune disease associated with
multiple symptoms that can flare up over time. Diagnosis of SLE can
be challenging. An objective of the project includes better
characterisation of the disease, where there is a high unmet need
for an effective therapy.
This project builds upon Oncimmune's broadening commercial
footprint to not only deliver diagnostic tests, through EarlyCDT
Lung and Liver, but also to partner with large pharmaceutical
companies by profiling autoantibodies and developing commercial
companion diagnostic tests through Oncimmune's ImmunoINSIGHTS
service business.
Dr Adam M Hill, CEO of Oncimmune said: "Genentech is a
pre-eminent biotechnology company, considered a leader in the
biotech industry today. This contract adds to the already
substantial pipeline of contracted revenue through our
ImmunoINSIGHTS business in FY2021 and provides another opportunity
to show how our NavigAID(TM) technology can assist partners in
increasing their ability to better assess where their medicines
could make an impact. We look forward to delivering this project
and contributing to the scientific understanding of lupus."
For further information:
Oncimmune Holdings plc
Adam Hill, Chief Executive Officer
Matthew Hall, Chief Financial Officer
contact@oncimmune.co.uk
Zeus Capital Limited (Nominated Adviser and Joint Broker)
Andrew Jones, Daniel Harris, Victoria Ayton
+44 (0)20 3829 5000
N+1 Singer (Joint Broker)
Aubrey Powell, Harry Gooden, Iqra Amin, James Fischer
+44 (0)20 7496 3000
WG Partners (Joint Broker)
David Wilson, Chris Lee
+44 (0)203 705 9321
Media enquiries:
FTI Consulting
Ben Atwell, Michael Trace, Alex Davis
Oncimmune@fticonsulting.com
+44 (0)20 3727 1000
About Oncimmune
Our intimate understanding of the human immune system enables us
to harness its sophisticated response to disease to detect cancer
earlier and to support the development of better therapies.
The key to improving cancer survival is early detection and
better selection for therapy. As a company, we are driven by our
passion to improve cancer survival and give people extra time.
Oncimmune's immunodiagnostic test, EarlyCDT, can detect and help
identify cancer on average four years earlier than standard
clinical diagnosis.
The unique combination of our core technology and understanding
of the immune system, powers our ImmunoINSIGHTS service; a
proprietary platform that enables life science organisations to
optimise drug development and delivery, leading to more effective,
targeted as well as safer treatments for patients.
Oncimmune was founded in 2002 and launched its platform
diagnostic technology in 2009, followed by the launch of its first
commercial tests, EarlyCDT Lung and EarlyCDT Liver. To date, over
200,000 tests have been performed for patients worldwide. EarlyCDT
Lung was also used in what is believed to be the largest randomised
controlled trial for the early detection of lung cancer using
biomarkers, the successful National Health Service (NHS) Early
detection of Cancer of the Lung ("ECLS") trial of 12,208 high-risk
smokers in Scotland. This trial demonstrated that EarlyCDT Lung
reduced the incidence of patients with late-stage lung cancer or
unclassified presentation at diagnosis, compared to standard
clinical practice.
Oncimmune, headquartered at its laboratory facility in
Nottingham, UK, has a discovery research centre in Dortmund,
Germany and a partner representative office in Shanghai, China.
Oncimmune joined the Alternative Investment Market (AIM) of the
London Stock Exchange in May 2016 under the ticker ONC.L.
What is NavigAID?
Oncimmune's NavigAID arrays are thoroughly validated containing
well defined antigen panels, largely encompassing markers of
interest for each of the disease types being investigated.
Our portfolio of panels includes out-of-the-box NavigAID arrays
for immuno-oncology and autoimmune diseases. These validated panels
are frequently used as the starting point for collaborations with
partners to add further markers of interest to their specific
therapy and its specific indication.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
CNTKKBBPOBKDFCB
(END) Dow Jones Newswires
September 23, 2020 02:00 ET (06:00 GMT)
Oncimmune (LSE:ONC)
Historical Stock Chart
From Apr 2024 to May 2024
Oncimmune (LSE:ONC)
Historical Stock Chart
From May 2023 to May 2024